



Belgian Cancer Registry

## CANCER FACT SHEET 2022

### MESOTHELIOMA

ICD-10 C45



## CONCEPTS AND ABBREVIATIONS

**Absolute numbers (N):** The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

**Average Annual Percentage Change (AAPC):** The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ( $=200 \times 1.05$ ) and 255/100,000 over 5 years ( $=200 \times (1.05)^5$ ).

**Crude Rate (CR):** The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

**ESR2013:** Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

**Net survival:** Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

**Stage:** Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8<sup>th</sup> edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

**95% CI:** 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.



1. CANCER INCIDENCE .....	5
1.1. Mesothelioma incidence: by region .....	5
1.1.1. Mesothelioma incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022.....	5
1.2. Mesothelioma incidence: by tumour stage .....	7
1.2.1. Mesothelioma incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	7
1.2.2. Mesothelioma incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....	7
1.2.3. Mesothelioma incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	8
1.3. Mesothelioma incidence: by tumour sublocation.....	9
1.3.1. Mesothelioma incidence by sublocation, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	9
2. CANCER INCIDENCE TRENDS .....	10
2.1. Mesothelioma incidence trends: by region.....	10
2.1.1. Mesothelioma incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	10
2.1.2. Mesothelioma incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	12
2.2. Mesothelioma incidence trends: by tumour stage .....	13
2.2.1. Mesothelioma incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards .....	13
2.3. Mesothelioma incidence trends: by tumour sublocation .....	15
2.3.1. Mesothelioma incidence trends by sublocation and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards...	15
2.4. Mesothelioma incidence trends: by age group .....	16
2.4.1. Mesothelioma incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	16
2.4.2. Mesothelioma incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	17
3. CANCER PREVALENCE .....	18
3.1. Mesothelioma prevalence: by region.....	18
3.1.1. Mesothelioma prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022 .....	18
4. CANCER SURVIVAL.....	19
4.1. Mesothelioma survival: by region .....	19
4.1.1. Mesothelioma survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022 .....	19
4.2. Mesothelioma survival: by tumour stage .....	21

4.2.1. Mesothelioma survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022 .....	21
4.2.2. Mesothelioma survival by pathological stage (pStage) and sex: number at risk and net survival probabilities, 2013-2022 .....	22
4.2.3. Mesothelioma survival by stage and sex: number at risk and net survival probabilities, 2013-2022 .....	23
5. CANCER SURVIVAL TRENDS.....	24
5.1. Mesothelioma survival trends: by tumour stage.....	24
5.1.1. Mesothelioma survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022.....	24
6. CANCER MORTALITY .....	26
6.1. Mesothelioma mortality: by region.....	26
6.1.1. Mesothelioma mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021 .....	26
7. CANCER MORTALITY TRENDS.....	28
7.1. Mesothelioma mortality trends: by region .....	28
7.1.1. Mesothelioma mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021 .....	28
7.1.2. Mesothelioma mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021 .....	30



# 1. CANCER INCIDENCE



## 1.1. Mesothelioma incidence: by region

1.1.1. Mesothelioma incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Males																						
<b>Belgium</b>	0	0	0	0	0	0	1	1	1	0	6	9	24	32	50	55	48	24	7	1	259	5.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.3]	[0.0]	[1.5]	[2.2]	[6.5]	[10.2]	[18.9]	[28.9]	[37.9]	[30.6]	[23.3]	[17.1]	[4.5]	(4.4; 5.6)
Brussels	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	4	1.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[3.6]	[4.7]	[6.1]	[8.2]	[0.0]	[0.0]	[0.0]	[0.0]	[0.7]	(0.0; 2.2)
Flanders	0	0	0	0	0	0	1	0	0	0	5	4	16	21	33	41	34	17	5	0	177	5.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[0.0]	[0.0]	[2.2]	[1.6]	[7.1]	[10.9]	[20.4]	[33.2]	[40.7]	[32.4]	[25.1]	[0.0]	[5.3]	(4.6; 6.2)
Wallonia	0	0	0	0	0	0	0	1	1	0	1	5	7	10	16	13	14	7	2	1	78	5.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.9]	[0.0]	[0.8]	[4.0]	[6.0]	[10.1]	[18.6]	[23.8]	[40.0]	[33.5]	[25.2]	[65.0]	[4.4]	(3.9; 6.2)
Females																						
<b>Belgium</b>	0	0	0	0	0	0	1	1	0	1	0	1	5	6	11	14	8	2	1	1	52	0.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.0]	[0.3]	[0.0]	[0.3]	[1.3]	[1.8]	[3.7]	[6.1]	[4.5]	[1.5]	[1.4]	[4.9]	[0.9]	(0.6; 1.1)
Brussels	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0	0	0	0	4	0.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[23.2]	[0.0]	[0.0]	[0.0]	[0.0]	[0.6]	(0.0; 1.8)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Flanders	0	0	0	0	0	0	1	0	0	1	0	0	4	5	8	4	6	1	1	1	32	0.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[0.0]	[0.5]	[0.0]	[0.0]	[1.8]	[2.5]	[4.6]	[2.8]	[5.4]	[1.2]	[2.3]	[8.3]	[0.9]	(0.5; 1.1)
Wallonia	0	0	0	0	0	0	0	1	0	0	0	1	1	1	3	6	2	1	0	0	16	0.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[0.0]	[0.0]	[0.8]	[0.8]	[0.9]	[3.0]	[8.5]	[3.8]	[2.5]	[0.0]	[0.0]	[0.9]	(0.4; 1.2)

## 1.2. Mesothelioma incidence: by tumour stage

1.2.1. Mesothelioma incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	6 [0.2]	42 [4.4]	44 [10.2]	92 [1.6]	1.8 (1.4; 2.1)	1 [0.0]	8 [0.8]	6 [0.9]	15 [0.3]	0.2 (0.1; 0.4)
II	1 [0.0]	4 [0.4]	8 [1.9]	13 [0.2]	0.3 (0.1; 0.4)	0 [0.0]	0 [0.0]	3 [0.5]	3 [0.1]	0.0 (0.0; 0.1)
III	4 [0.1]	28 [3.0]	41 [9.5]	73 [1.3]	1.4 (1.1; 1.7)	0 [0.0]	5 [0.5]	7 [1.1]	12 [0.2]	0.2 (0.1; 0.3)
IV	2 [0.1]	18 [1.9]	21 [4.9]	41 [0.7]	0.8 (0.5; 1.0)	1 [0.0]	4 [0.4]	3 [0.5]	8 [0.1]	0.1 (0.0; 0.2)
X/NA	5 [0.1]	14 [1.5]	21 [4.9]	40 [0.7]	0.8 (0.5; 1.0)	2 [0.1]	5 [0.5]	7 [1.1]	14 [0.2]	0.2 (0.1; 0.3)

1.2.2. Mesothelioma incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	1 [0.0]	7 [0.7]	0 [0.0]	8 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	2 [0.2]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)
II	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)	1 [0.0]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)
III	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
IV	0 [0.0]	2 [0.2]	1 [0.2]	3 [0.1]	0.1 (0.0; 0.1)	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)
X/NA	17 [0.5]	95 [10.0]	134 [31.1]	246 [4.3]	4.8 (4.2; 5.4)	3 [0.1]	19 [1.9]	26 [4.1]	48 [0.8]	0.8 (0.5; 1.0)

1.2.3. Mesothelioma incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Stage	Males					Females				
	N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
<b>I</b>	6 [0.2]	42 [4.4]	44 [10.2]	92 [1.6]	1.8 (1.4; 2.1)	0 [0.0]	8 [0.8]	6 [0.9]	14 [0.2]	0.2 (0.1; 0.3)
<b>II</b>	1 [0.0]	4 [0.4]	8 [1.9]	13 [0.2]	0.3 (0.1; 0.4)	1 [0.0]	0 [0.0]	3 [0.5]	4 [0.1]	0.1 (0.0; 0.1)
<b>III</b>	4 [0.1]	29 [3.1]	41 [9.5]	74 [1.3]	1.4 (1.1; 1.7)	0 [0.0]	5 [0.5]	7 [1.1]	12 [0.2]	0.2 (0.1; 0.3)
<b>IV</b>	2 [0.1]	18 [1.9]	21 [4.9]	41 [0.7]	0.8 (0.5; 1.0)	1 [0.0]	5 [0.5]	3 [0.5]	9 [0.2]	0.2 (0.1; 0.2)
<b>X/NA</b>	5 [0.1]	13 [1.4]	21 [4.9]	39 [0.7]	0.8 (0.5; 1.0)	2 [0.1]	4 [0.4]	7 [1.1]	13 [0.2]	0.2 (0.1; 0.3)



### 1.3. Mesothelioma incidence: by tumour sublocation

1.3.1. Mesothelioma incidence by sublocation, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Sublocation	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
<b>Pleural</b>	13 [0.4]	102 [10.8]	126 [29.2]	241 [4.2]	4.6 (4.1; 5.2)	2 [0.1]	19 [1.9]	25 [3.9]	46 [0.8]	0.7 (0.5; 0.9)
<b>Peritoneal</b>	5 [0.1]	4 [0.4]	6 [1.4]	15 [0.3]	0.3 (0.1; 0.4)	2 [0.1]	3 [0.3]	0 [0.0]	5 [0.1]	0.1 (0.0; 0.2)
<b>Other and unspecified</b>	0 [0.0]	0 [0.0]	3 [0.7]	3 [0.1]	0.1 (0.0; 0.1)	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.1)

## 2. CANCER INCIDENCE TRENDS



### 2.1. Mesothelioma incidence trends: by region

2.1.1. Mesothelioma incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
Belgium	<b>N</b>	209	208	201	192	205	193	204	223	236	228	245	240	221	238	232	238	214	242	259			
	<b>CR</b>	4.1	4.1	3.9	3.7	3.9	3.7	3.8	4.2	4.4	4.2	4.5	4.4	4.0	4.3	4.1	4.2	3.8	4.3	4.5			
	<b>ESR2013</b>	5.2	5.3	4.7	4.6	4.8	4.5	4.6	5.1	5.5	5.0	5.3	5.2	4.8	5.0	4.7	4.8	4.3	4.7	5.0	-0.3 (-0.9; 0.3)	2004-2022	
																					0.1 (-0.8; 1.1)	2004-2016	
																						-1.1 (-3.1; 0.9)	2017-2022
Brussels	<b>N</b>	8	8	8	12	6	7	5	5	8	10	6	11	10	7	4	9	8	11	4			
	<b>CR</b>	1.7	1.7	1.6	2.4	1.2	1.4	0.9	0.9	1.4	1.8	1.1	1.9	1.7	1.2	0.7	1.5	1.3	1.8	0.7			
	<b>ESR2013</b>	2.4	2.5	2.5	3.5	1.8	2.0	1.6	1.5	2.2	3.2	1.8	3.2	3.1	2.1	0.9	2.5	2.4	2.9	1.1	-1.4 (-4.5; 1.8)	2004-2022	
Flanders	<b>N</b>	138	140	146	134	144	135	148	165	164	156	176	162	151	156	168	156	143	168	177			
	<b>CR</b>	4.7	4.7	4.9	4.4	4.7	4.4	4.8	5.3	5.2	5.0	5.6	5.1	4.7	4.8	5.2	4.8	4.4	5.1	5.3			
	<b>ESR2013</b>	5.5	5.9	5.5	5.2	5.4	5.0	5.4	6.1	6.1	5.5	6.1	5.6	5.3	5.1	5.4	5.0	4.5	5.2	5.4	-0.5 (-1.1; 0.0)	2004-2022	
																					0.5 (-0.7; 1.7)	2004-2014	
																						-1.8 (-3.3; -0.3)	2015-2022
Wallonia	<b>N</b>	63	60	47	46	55	51	51	53	64	62	63	67	60	75	60	73	63	63	78			
	<b>CR</b>	3.8	3.6	2.8	2.8	3.3	3.0	3.0	3.1	3.7	3.6	3.6	3.8	3.4	4.3	3.4	4.1	3.5	3.5	4.4			

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
<b>ESR2013</b>	5.4	4.9	3.8	3.6	4.5	4.0	3.9	3.8	5.1	4.4	4.6	4.6	4.3	5.3	4.1	5.1	4.2	4.0	5.1	0.3 (-0.8; 1.5)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Mesothelioma incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
Belgium <b>N</b>	26	46	40	47	50	41	52	51	44	44	49	65	54	62	62	54	48	57	52				
	<b>CR</b>	0.5	0.9	0.7	0.9	0.9	0.7	0.9	0.9	0.8	0.8	0.9	1.1	0.9	1.1	1.1	0.9	0.8	1.0	0.9			
	<b>ESR2013</b>	0.5	0.9	0.8	0.9	0.9	0.7	0.9	0.9	0.8	0.8	0.8	1.1	0.9	1.0	1.0	0.9	0.8	0.9	0.8	0.9 (-0.4; 2.3)	2004-2022	
																					2.7 (0.7; 4.9)	2004-2016	
																						-2.5 (-6.9; 2.0)	2017-2022
Brussels <b>N</b>	1	3	2	5	0	3	6	3	3	2	3	9	3	2	5	5	4	5	4				
	<b>CR</b>	0.2	0.6	0.4	0.9	0.0	0.5	1.1	0.5	0.5	0.3	0.5	1.5	0.5	0.3	0.8	0.8	0.6	0.8	0.6			
	<b>ESR2013</b>	0.2	0.7	0.5	1.1	0.0	0.5	1.2	0.7	0.7	0.4	0.7	1.8	0.6	0.5	0.8	1.1	0.8	1.0	0.9	NA	2004-2022	
Flanders <b>N</b>	19	33	23	32	36	28	36	39	29	29	30	38	43	37	46	38	29	30	32				
	<b>CR</b>	0.6	1.1	0.7	1.0	1.2	0.9	1.1	1.2	0.9	0.9	0.9	1.2	1.3	1.1	1.4	1.1	0.9	0.9	0.9			
	<b>ESR2013</b>	0.6	1.1	0.8	1.0	1.1	0.8	1.1	1.1	0.9	0.8	0.9	1.0	1.2	1.0	1.3	1.1	0.7	0.8	0.8	0.1 (-1.5; 1.8)	2004-2022	
																					2.6 (-0.2; 5.6)	2004-2015	
																						-3.6 (-8.1; 1.0)	2016-2022
Wallonia <b>N</b>	6	10	15	10	14	10	10	9	12	13	16	18	8	23	11	11	15	22	16				
	<b>CR</b>	0.3	0.6	0.9	0.6	0.8	0.6	0.6	0.5	0.7	0.7	0.9	1.0	0.4	1.2	0.6	0.6	0.8	1.2	0.9			
	<b>ESR2013</b>	0.4	0.6	0.9	0.6	0.8	0.6	0.6	0.5	0.7	0.7	0.8	0.9	0.4	1.1	0.6	0.6	0.8	1.1	0.8	2.3 (-0.2; 4.8)	2004-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.2. Mesothelioma incidence trends: by tumour stage

2.2.1. Mesothelioma incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Stage	Males							Females							
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
<b>I</b>	<b>N</b>	91	65	92	87	92		18	22	19	14	14			
	<b>CR</b>	1.6	1.2	1.6	1.5	1.6		0.3	0.4	0.3	0.2	0.2			
	<b>ESR2013</b>	1.8	1.3	1.9	1.7	1.8	9.3 (6.2; 12.6)	2004-2022	0.3	0.4	0.3	0.2	0.2	17.5 (11.3; 24.0)	2004-2022
							-7.3 (-16.1; 2.5)	2004-2010							
						21.4 (6.9; 37.8)	2011-2014								
						17.5 (9.6; 25.9)	2015-2022								
<b>II</b>	<b>N</b>	14	12	11	13	13		4	2	2	3	4			
	<b>CR</b>	0.3	0.2	0.2	0.2	0.2		0.1	0.0	0.0	0.1	0.1			
	<b>ESR2013</b>	0.3	0.2	0.2	0.2	0.3	-3.2 (-5.8; -0.5)	2004-2022	0.1	0.0	0.0	0.0	0.1	-3.7 (-8.8; 1.8)	2004-2022
							3.3 (-1.4; 8.1)	2004-2014							
						-18.2 (-27.1; -8.2)	2015-2018								
						-2.6 (-15.8; 12.6)	2019-2022								
<b>III</b>	<b>N</b>	47	73	44	77	74		17	11	9	16	12			
	<b>CR</b>	0.8	1.3	0.8	1.4	1.3		0.3	0.2	0.2	0.3	0.2			
	<b>ESR2013</b>	1.0	1.5	0.9	1.5	1.4	5.4 (3.1; 7.7)	2004-2022	0.3	0.2	0.1	0.2	0.2	7.4 (4.5; 10.3)	2004-2022
<b>IV</b>	<b>N</b>	24	32	26	27	41		8	7	4	7	9			
	<b>CR</b>	0.4	0.6	0.5	0.5	0.7		0.1	0.1	0.1	0.1	0.2			
	<b>ESR2013</b>	0.5	0.6	0.5	0.5	0.8	-1.6 (-4.4; 1.4)	2004-2022	0.1	0.1	0.1	0.1	0.2	1.9 (-1.5; 5.4)	2004-2022
							3.3 (-1.9; 8.7)	2004-2015						9.6 (2.6; 17.1)	2004-2014
						-8.8 (-16.3; -0.6)	2016-2022						-7.0 (-14.6; 1.2)	2015-2022	

Stage	Males							Females						
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
<b>X/NA N</b>	56	56	41	38	39			15	12	14	17	13		
<b>CR</b>	1.0	1.0	0.7	0.7	0.7			0.3	0.2	0.2	0.3	0.2		
<b>ESR2013</b>	1.2	1.2	0.8	0.7	0.8	-7.5 (-8.1; -6.9)	2004-2022	0.2	0.2	0.2	0.3	0.2	-4.6 (-6.3; -2.9)	2004-2022
						-2.9 (-4.2; -1.7)	2004-2014						0.1 (-3.8; 4.1)	2004-2013
						-13.0 (-14.4; -11.6)	2015-2022						-9.1 (-12.6; -5.4)	2014-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.3. Mesothelioma incidence trends: by tumour sublocation

2.3.1. Mesothelioma incidence trends by sublocation and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Sublocation		Males						Females							
		2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
Pleural	<b>N</b>	225	219	203	228	241			53	46	38	48	46		
	<b>CR</b>	4.0	3.9	3.6	4.0	4.2			0.9	0.8	0.7	0.8	0.8		
	<b>ESR2013</b>	4.6	4.4	4.1	4.5	4.6	-0.2 (-0.9; 0.4)	2004-2022	0.9	0.8	0.6	0.8	0.7	0.9 (-0.5; 2.3)	2004-2022
						0.0 (-0.7; 0.7)	2004-2018								
						-1.1 (-4.1; 2.0)	2019-2022								
Peritoneal	<b>N</b>	6	14	9	14	15			8	8	10	9	5		
	<b>CR</b>	0.1	0.2	0.2	0.2	0.3			0.1	0.1	0.2	0.2	0.1		
	<b>ESR2013</b>	0.1	0.3	0.2	0.3	0.3	-1.9 (-4.4; 0.6)	2004-2022	0.1	0.1	0.2	0.1	0.1	2.6 (-1.0; 6.4)	2004-2022
						1.2 (-4.4; 7.2)	2004-2013						7.5 (2.3; 12.9)	2004-2017	
						-5.0 (-10.3; 0.6)	2014-2022						-9.0 (-21.4; 5.3)	2018-2022	
Other and unspecified	<b>N</b>	1	5	2	0	3			1	0	0	0	1		
	<b>CR</b>	0.0	0.1	0.0	0.0	0.1			0.0	0.0	0.0	0.0	0.0		
	<b>ESR2013</b>	0.0	0.1	0.0	0.0	0.1	NA	2004-2022	0.0	0.0	0.0	0.0	0.0	NA	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.4. Mesothelioma incidence trends: by age group

2.4.1. Mesothelioma incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
<b>15-59 N</b>	35	28	42	30	31	29	26	37	21	31	33	28	14	23	20	15	12	18	18			
	<b>CR</b>	1.1	0.9	1.3	0.9	1.0	0.9	0.8	1.1	0.6	0.9	1.0	0.8	0.4	0.7	0.6	0.4	0.4	0.5	0.5		
	<b>ESR2013</b>	1.2	0.9	1.4	1.0	1.0	0.9	0.8	1.2	0.6	0.9	1.0	0.8	0.4	0.7	0.6	0.4	0.3	0.5	0.5	-5.5 (-7.4; -3.6)	2004-2022
<b>60-74 N</b>	109	109	100	95	109	93	93	95	111	102	110	114	97	96	104	112	91	106	106			
	<b>CR</b>	16.0	15.9	14.6	13.6	15.3	12.8	12.5	12.6	14.4	13.0	13.8	14.0	11.7	11.2	11.8	12.5	9.9	11.3	11.2		
	<b>ESR2013</b>	16.0	15.9	14.6	13.7	15.6	13.4	13.0	13.1	15.4	13.6	14.5	14.9	12.1	11.9	12.3	12.9	10.2	11.5	11.5	-1.7 (-2.4; -1.1)	2004-2022
<b>75+</b>	<b>N</b>	65	71	59	67	65	71	85	91	104	95	102	98	110	119	108	111	111	118	135		
	<b>CR</b>	22.2	23.5	18.8	20.6	19.3	20.5	24.0	25.2	28.2	25.3	26.6	25.0	27.9	30.1	27.2	27.5	26.8	28.4	31.3		
	<b>ESR2013</b>	21.0	23.6	16.9	19.2	18.2	18.8	22.0	25.0	28.4	24.7	25.6	24.6	28.3	28.9	26.1	26.9	26.5	27.8	30.9	2.5 (1.5; 3.5)	2004-2022
																					3.2 (1.2; 5.2)	2004-2014
																					1.6 (-0.9; 4.1)	2015-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.



2.4.2. Mesothelioma incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
<b>15-59</b>	<b>N</b>	7	9	11	9	9	5	10	9	7	12	6	11	8	8	10	9	5	4	4			
	<b>CR</b>	0.2	0.3	0.3	0.3	0.3	0.2	0.3	0.3	0.2	0.4	0.2	0.3	0.2	0.2	0.3	0.3	0.2	0.1	0.1			
	<b>ESR2013</b>	0.2	0.3	0.4	0.3	0.3	0.2	0.3	0.3	0.2	0.4	0.2	0.3	0.2	0.2	0.3	0.3	0.1	0.1	0.1	-3.8 (-6.2; -1.4)	2004-2022	
																					0.5 (-3.8; 4.9)	2004-2015	
																						-10.2 (-16.4; -3.5)	2016-2022
<b>60-74</b>	<b>N</b>	11	29	17	18	20	13	25	18	20	13	15	23	21	23	22	27	21	27	22			
	<b>CR</b>	1.4	3.7	2.2	2.3	2.5	1.6	3.1	2.2	2.4	1.5	1.7	2.6	2.4	2.5	2.3	2.8	2.1	2.7	2.2			
	<b>ESR2013</b>	1.3	3.6	2.2	2.3	2.6	1.6	3.1	2.3	2.4	1.6	1.8	2.6	2.4	2.6	2.4	2.9	2.2	2.7	2.2	0.7 (-1.4; 2.9)	2004-2022	
<b>75+</b>	<b>N</b>	8	8	12	20	21	23	17	24	17	19	28	31	25	31	30	18	22	26	26			
	<b>CR</b>	1.5	1.5	2.2	3.6	3.7	4.0	2.9	4.0	2.8	3.1	4.6	5.0	4.1	5.1	4.9	2.9	3.5	4.2	4.1			
	<b>ESR2013</b>	1.5	1.4	2.2	3.5	3.6	3.9	2.6	3.9	3.0	3.2	4.8	4.9	4.1	5.0	5.0	3.1	3.7	4.3	4.4	6.0 (3.7; 8.5)	2004-2022	
																						19.7 (8.8; 31.6)	2004-2009
																						1.2 (-8.2; 11.6)	2010-2013
																						1.2 (-3.2; 5.9)	2014-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

### 3. CANCER PREVALENCE



#### 3.1. Mesothelioma prevalence: by region

3.1.1. *Mesothelioma prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022*

Region		Males				Females			
		1-year	5-year	10-year	15-year	1-year	5-year	10-year	15-year
Belgium	<b>N</b>	185	366	408	420	37	103	132	136
	<b>CR</b>	3.2	6.4	7.1	7.3	0.6	1.7	2.2	2.3
	<b>ESR2013</b>	3.5	6.8	7.6	7.8	0.6	1.6	2.1	2.1
Brussels	<b>N</b>	2	10	10	10	3	8	9	9
	<b>CR</b>	0.3	1.6	1.6	1.6	0.5	1.3	1.4	1.4
	<b>ESR2013</b>	0.5	2.3	2.3	2.3	0.6	1.7	2.0	2.0
Flanders	<b>N</b>	124	246	276	286	23	63	84	85
	<b>CR</b>	3.7	7.3	8.2	8.5	0.7	1.8	2.5	2.5
	<b>ESR2013</b>	3.7	7.3	8.2	8.5	0.6	1.7	2.2	2.2
Wallonia	<b>N</b>	59	110	122	124	11	32	39	42
	<b>CR</b>	3.3	6.1	6.8	6.9	0.6	1.7	2.1	2.2
	<b>ESR2013</b>	3.8	6.9	7.6	7.7	0.6	1.6	1.9	2.0



### 4.1. Mesothelioma survival: by region

4.1.1. Mesothelioma survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All	2,898	51.3% (49.4%; 53.2%)	18.1% (16.6%; 19.8%)	10.7% (9.3%; 12.2%)	5.2% (3.7%; 7.3%)
Males						
Belgium	All ages	2,351	49.9% (47.8%; 52.1%)	16.2% (14.6%; 18.0%)	8.9% (7.5%; 10.5%)	3.5% (2.1%; 5.8%)
	15-59	212	65.0% (58.8%; 71.8%)	29.0% (23.3%; 36.1%)	23.0% (17.7%; 30.0%)	11.4% (7.0%; 18.6%)
	60-74	1,035	59.8% (56.8%; 62.9%)	20.8% (18.3%; 23.7%)	10.6% (8.5%; 13.3%)	2.7% (1.3%; 5.6%)
	75+	1,104	37.8% (34.8%; 41.0%)	9.5% (7.6%; 11.9%)	4.4% (2.9%; 6.6%)	1.7% (0.4%; 7.2%)
Brussels	All ages	80	45.7% (35.7%; 58.5%)	16.1% (9.5%; 27.1%)	5.0% (1.7%; 14.7%)	FU<10y
	15-59	9	N<50	N<50	N<50	N<50
	60-74	38	N<50	N<50	N<50	N<50
	75+	33	N<50	N<50	N<50	N<50
Flanders	All ages	1,609	50.2% (47.7%; 52.8%)	16.4% (14.5%; 18.6%)	9.3% (7.6%; 11.3%)	4.1% (2.3%; 7.2%)
	15-59	133	65.8% (58.2%; 74.4%)	30.8% (23.7%; 40.1%)	24.8% (18.1%; 33.9%)	14.9% (9.1%; 24.2%)
	60-74	698	62.0% (58.4%; 65.8%)	22.3% (19.1%; 25.9%)	10.9% (8.3%; 14.2%)	3.1% (1.5%; 6.3%)
	75+	778	36.9% (33.5%; 40.7%)	8.8% (6.7%; 11.5%)	5.0% (3.2%; 7.8%)	2.3% (0.5%; 9.9%)
Wallonia	All ages	662	49.8% (46.0%; 54.0%)	15.8% (12.8%; 19.4%)	8.2% (5.8%; 11.5%)	1.4% (0.4%; 4.9%)

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	<b>15-59</b>	70	61.7% (51.3%; 74.2%)	24.6% (16.1%; 37.8%)	19.4% (11.2%; 33.4%)	FU<10y
	<b>60-74</b>	299	56.5% (51.1%; 62.6%)	17.6% (13.5%; 22.9%)	11.1% (7.5%; 16.3%)	2.7% (0.8%; 9.1%)
	<b>75+</b>	293	40.2% (34.6%; 46.6%)	11.7% (7.7%; 17.7%)	2.6% (1.0%; 7.0%)	FU<10y
Females						
<b>Belgium</b>	<b>All ages</b>	547	57.1% (53.0%; 61.5%)	26.4% (22.6%; 30.7%)	18.5% (14.9%; 22.9%)	12.2% (8.3%; 17.9%)
	<b>15-59</b>	77	79.5% (70.9%; 89.0%)	51.4% (41.2%; 64.1%)	32.5% (23.1%; 45.8%)	24.7% (15.9%; 38.4%)
	<b>60-74</b>	214	62.5% (56.3%; 69.4%)	30.4% (24.5%; 37.8%)	22.2% (16.5%; 29.9%)	13.2% (7.2%; 24.2%)
	<b>75+</b>	256	45.9% (39.9%; 52.7%)	15.2% (10.9%; 21.1%)	11.5% (7.3%; 18.0%)	FU<10y
Brussels	<b>All ages</b>	42	N<50	N<50	N<50	N<50
	<b>15-59</b>	4	N<50	N<50	N<50	N<50
	<b>60-74</b>	13	N<50	N<50	N<50	N<50
	<b>75+</b>	25	N<50	N<50	N<50	N<50
Flanders	<b>All ages</b>	352	56.2% (51.1%; 61.8%)	26.0% (21.5%; 31.4%)	17.8% (13.7%; 23.2%)	13.2% (8.9%; 19.6%)
	<b>15-59</b>	55	82.1% (72.5%; 92.8%)	52.6% (40.9%; 67.7%)	31.8% (21.3%; 47.5%)	29.1% (18.6%; 45.4%)
	<b>60-74</b>	143	61.0% (53.4%; 69.7%)	27.7% (20.8%; 36.8%)	19.7% (13.3%; 29.0%)	9.4% (3.9%; 22.5%)
	<b>75+</b>	154	42.6% (35.1%; 51.6%)	14.5% (9.4%; 22.3%)	11.4% (6.5%; 20.1%)	FU<10y
Wallonia	<b>All ages</b>	153	56.5% (49.0%; 65.2%)	27.8% (20.9%; 36.9%)	22.5% (15.4%; 32.8%)	12.3% (5.1%; 29.2%)
	<b>15-59</b>	18	N<50	N<50	N<50	N<50
	<b>60-74</b>	58	62.7% (51.4%; 76.5%)	37.2% (26.2%; 52.7%)	30.3% (19.7%; 46.7%)	FU<10y
	<b>75+</b>	77	48.2% (37.9%; 61.4%)	16.5% (9.3%; 29.3%)	14.0% (6.7%; 29.0%)	FU<10y

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

## 4.2. Mesothelioma survival: by tumour stage

### 4.2.1. Mesothelioma survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022

cStage	Net Survival Probability, 2013-2022						
	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Total</b>	2,898	51.3% (49.4%; 53.2%)	29.1% (27.4%; 31.0%)	18.1% (16.6%; 19.8%)	13.2% (11.8%; 14.8%)	10.7% (9.3%; 12.2%)	5.2% (3.7%; 7.3%)
<b>Males</b>							
<b>All</b>	2,351	49.9% (47.8%; 52.1%)	27.3% (25.5%; 29.4%)	16.2% (14.6%; 18.0%)	11.6% (10.1%; 13.2%)	8.9% (7.5%; 10.5%)	3.5% (2.1%; 5.8%)
<b>I</b>	612	59.6% (55.6%; 63.9%)	34.1% (30.3%; 38.5%)	20.3% (16.9%; 24.3%)	15.2% (12.1%; 19.2%)	11.5% (8.5%; 15.7%)	8.8% (4.9%; 16.0%)
<b>II</b>	181	59.9% (52.8%; 67.9%)	32.1% (25.6%; 40.2%)	17.3% (12.2%; 24.4%)	15.3% (10.4%; 22.4%)	9.4% (5.4%; 16.4%)	2.2% (0.5%; 9.4%)
<b>III</b>	506	48.9% (44.6%; 53.7%)	25.7% (21.9%; 30.1%)	14.9% (11.5%; 19.2%)	10.2% (7.3%; 14.2%)	7.4% (4.8%; 11.2%)	FU<10y
<b>IV</b>	381	36.2% (31.6%; 41.5%)	17.6% (14.0%; 22.2%)	9.5% (6.7%; 13.3%)	5.1% (3.1%; 8.3%)	3.4% (1.8%; 6.5%)	FU<10y
<b>X/NA</b>	671	47.0% (43.2%; 51.1%)	26.7% (23.4%; 30.6%)	17.1% (14.2%; 20.6%)	11.9% (9.4%; 15.1%)	10.3% (7.9%; 13.5%)	3.6% (1.7%; 7.9%)
<b>Females</b>							
<b>All</b>	547	57.1% (53.0%; 61.5%)	36.9% (32.8%; 41.4%)	26.4% (22.6%; 30.7%)	20.3% (16.7%; 24.6%)	18.5% (14.9%; 22.9%)	12.2% (8.3%; 17.9%)
<b>I</b>	130	62.3% (54.2%; 71.5%)	40.5% (32.6%; 50.5%)	31.9% (24.3%; 42.0%)	28.1% (20.5%; 38.5%)	27.1% (19.2%; 38.3%)	20.5% (10.9%; 38.6%)
<b>II</b>	38	N<50	N<50	N<50	N<50	N<50	N<50
<b>III</b>	102	55.3% (46.3%; 66.1%)	34.1% (25.7%; 45.4%)	16.4% (10.0%; 26.8%)	13.5% (7.7%; 23.7%)	10.5% (5.4%; 20.4%)	3.4% (0.8%; 14.5%)
<b>IV</b>	83	47.7% (38.0%; 60.0%)	25.5% (17.5%; 37.1%)	17.2% (10.5%; 28.1%)	8.6% (4.1%; 17.9%)	5.3% (2.0%; 13.7%)	FU<10y
<b>X/NA</b>	194	57.0% (50.2%; 64.7%)	41.0% (34.2%; 49.1%)	32.4% (26.0%; 40.4%)	24.8% (18.7%; 32.8%)	25.1% (18.8%; 33.6%)	18.7% (11.7%; 29.9%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<years in the table.

4.2.2. Mesothelioma survival by pathological stage (pStage) and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Total</b>	2,898	51.3% (49.4%; 53.2%)	29.1% (27.4%; 31.0%)	18.1% (16.6%; 19.8%)	13.2% (11.8%; 14.8%)	10.7% (9.3%; 12.2%)	5.2% (3.7%; 7.3%)
<b>Males</b>							
<b>All</b>	2,351	49.9% (47.8%; 52.1%)	27.3% (25.5%; 29.4%)	16.2% (14.6%; 18.0%)	11.6% (10.1%; 13.2%)	8.9% (7.5%; 10.5%)	3.5% (2.1%; 5.8%)
<b>I</b>	64	85.2% (76.3%; 95.2%)	68.7% (57.2%; 82.4%)	50.8% (38.6%; 66.7%)	37.9% (26.1%; 55.0%)	28.0% (16.8%; 47.0%)	FU<10y
<b>II</b>	25	N<50	N<50	N<50	N<50	N<50	N<50
<b>III</b>	53	80.7% (70.4%; 92.5%)	52.8% (40.6%; 68.7%)	32.7% (21.8%; 49.1%)	33.5% (22.4%; 50.2%)	29.2% (18.4%; 46.3%)	FU<10y
<b>IV</b>	30	N<50	N<50	N<50	N<50	N<50	N<50
<b>X/NA</b>	2,179	48.0% (45.8%; 50.2%)	25.5% (23.6%; 27.5%)	14.7% (13.1%; 16.5%)	10.1% (8.6%; 11.7%)	7.7% (6.4%; 9.3%)	3.1% (1.8%; 5.5%)
<b>Females</b>							
<b>All</b>	547	57.1% (53.0%; 61.5%)	36.9% (32.8%; 41.4%)	26.4% (22.6%; 30.7%)	20.3% (16.7%; 24.6%)	18.5% (14.9%; 22.9%)	12.2% (8.3%; 17.9%)
<b>I</b>	20	N<50	N<50	N<50	N<50	N<50	N<50
<b>II</b>	5	N<50	N<50	N<50	N<50	N<50	N<50
<b>III</b>	18	N<50	N<50	N<50	N<50	N<50	N<50
<b>IV</b>	10	N<50	N<50	N<50	N<50	N<50	N<50
<b>X/NA</b>	494	55.2% (50.8%; 59.9%)	34.2% (30.0%; 38.9%)	25.1% (21.2%; 29.6%)	18.8% (15.2%; 23.3%)	16.8% (13.2%; 21.3%)	11.6% (7.7%; 17.7%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

4.2.3. Mesothelioma survival by stage and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Total</b>	2,898	51.3% (49.4%; 53.2%)	29.1% (27.4%; 31.0%)	18.1% (16.6%; 19.8%)	13.2% (11.8%; 14.8%)	10.7% (9.3%; 12.2%)	5.2% (3.7%; 7.3%)
<b>Males</b>							
<b>All</b>	2,351	49.9% (47.8%; 52.1%)	27.3% (25.5%; 29.4%)	16.2% (14.6%; 18.0%)	11.6% (10.1%; 13.2%)	8.9% (7.5%; 10.5%)	3.5% (2.1%; 5.8%)
<b>I</b>	612	59.8% (55.8%; 64.1%)	34.5% (30.6%; 38.9%)	21.5% (18.1%; 25.6%)	15.7% (12.5%; 19.7%)	12.0% (8.9%; 16.1%)	9.3% (5.1%; 16.7%)
<b>II</b>	186	58.2% (51.2%; 66.2%)	32.9% (26.4%; 40.9%)	18.0% (12.9%; 25.1%)	16.0% (11.1%; 23.2%)	9.8% (5.8%; 16.6%)	4.0% (1.3%; 11.7%)
<b>III</b>	521	50.2% (45.9%; 54.9%)	26.5% (22.7%; 30.8%)	14.8% (11.6%; 19.1%)	10.7% (7.8%; 14.7%)	8.0% (5.4%; 11.8%)	FU<10y
<b>IV</b>	388	36.9% (32.3%; 42.2%)	17.8% (14.2%; 22.4%)	9.9% (7.1%; 13.8%)	5.6% (3.5%; 8.9%)	4.1% (2.3%; 7.3%)	FU<10y
<b>X/NA</b>	644	45.8% (41.9%; 50.0%)	25.5% (22.1%; 29.3%)	15.7% (12.9%; 19.2%)	10.7% (8.2%; 13.8%)	9.2% (6.9%; 12.4%)	3.2% (1.4%; 7.4%)
<b>Females</b>							
<b>All</b>	547	57.1% (53.0%; 61.5%)	36.9% (32.8%; 41.4%)	26.4% (22.6%; 30.7%)	20.3% (16.7%; 24.6%)	18.5% (14.9%; 22.9%)	12.2% (8.3%; 17.9%)
<b>I</b>	129	62.1% (53.9%; 71.4%)	40.8% (32.7%; 50.8%)	30.4% (22.8%; 40.4%)	26.6% (19.2%; 36.9%)	25.7% (18.0%; 36.6%)	17.1% (8.7%; 33.6%)
<b>II</b>	35	N<50	N<50	N<50	N<50	N<50	N<50
<b>III</b>	108	56.0% (47.2%; 66.4%)	34.2% (26.0%; 45.0%)	17.8% (11.3%; 27.9%)	15.3% (9.2%; 25.3%)	12.7% (7.1%; 22.5%)	4.0% (1.0%; 16.6%)
<b>IV</b>	87	49.1% (39.5%; 61.0%)	26.8% (18.8%; 38.2%)	17.2% (10.6%; 28.0%)	8.6% (4.2%; 17.8%)	5.3% (2.0%; 13.7%)	FU<10y
<b>X/NA</b>	188	56.6% (49.8%; 64.5%)	40.7% (33.8%; 48.9%)	33.0% (26.4%; 41.2%)	25.0% (18.8%; 33.3%)	25.4% (19.0%; 34.1%)	19.6% (12.2%; 31.3%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.



### 5.1. Mesothelioma survival trends: by tumour stage

#### 5.1.1. Mesothelioma survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2008-2012	All	1,056	47.5% (44.5%; 50.7%)	12.2% (10.2%; 14.5%)	5.6% (4.2%; 7.4%)	238	49.0% (42.9%; 55.9%)	17.5% (13.1%; 23.3%)	7.8% (5.0%; 12.4%)
	I	76	65.7% (55.4%; 77.9%)	12.9% (7.1%; 23.5%)	5.8% (2.3%; 14.8%)	12	N<50	N<50	N<50
	II	107	50.9% (42.1%; 61.6%)	17.8% (11.7%; 27.2%)	8.1% (4.2%; 15.7%)	18	N<50	N<50	N<50
	III	184	50.9% (44.0%; 58.9%)	16.0% (11.3%; 22.6%)	5.4% (2.8%; 10.4%)	26	N<50	N<50	N<50
	IV	175	38.2% (31.5%; 46.4%)	3.2% (1.4%; 7.6%)	0.7% (0.1%; 3.5%)	40	N<50	N<50	N<50
	X/NA	514	46.1% (41.8%; 50.8%)	12.6% (9.9%; 16.1%)	6.8% (4.7%; 9.7%)	142	52.0% (44.2%; 61.2%)	18.4% (12.8%; 26.4%)	8.5% (4.8%; 15.0%)
2013-2017	All	1,167	49.1% (46.2%; 52.2%)	14.6% (12.6%; 17.0%)	8.4% (6.8%; 10.4%)	274	55.6% (49.9%; 62.1%)	23.2% (18.5%; 29.1%)	16.5% (12.2%; 22.1%)
	I	185	61.2% (54.2%; 69.1%)	19.5% (14.2%; 26.7%)	11.4% (7.3%; 17.7%)	42	N<50	N<50	N<50
	II	123	56.8% (48.3%; 66.7%)	16.4% (10.7%; 25.2%)	8.7% (4.6%; 16.4%)	20	N<50	N<50	N<50
	III	206	52.3% (45.6%; 59.8%)	14.3% (10.1%; 20.4%)	9.3% (5.8%; 14.9%)	43	N<50	N<50	N<50
	IV	238	37.4% (31.6%; 44.3%)	10.6% (7.2%; 15.6%)	4.4% (2.3%; 8.3%)	52	42.9% (31.3%; 58.8%)	13.3% (6.6%; 26.8%)	4.4% (1.3%; 14.9%)
	X/NA	415	46.6% (41.9%; 51.9%)	14.4% (11.2%; 18.5%)	8.8% (6.2%; 12.5%)	117	59.7% (51.1%; 69.7%)	31.1% (23.3%; 41.7%)	26.0% (18.4%; 36.9%)
2018-2022	All	1,184	50.7% (47.8%; 53.8%)	18.1% (15.6%; 20.9%)	8.6% (6.2%; 11.8%)	273	58.5% (52.8%; 64.9%)	29.9% (24.4%; 36.7%)	19.8% (14.2%; 27.6%)
	I	427	59.2% (54.4%; 64.4%)	22.6% (18.3%; 27.9%)	11.4% (7.1%; 18.3%)	87	65.0% (55.4%; 76.3%)	31.7% (22.5%; 44.6%)	29.6% (19.8%; 44.1%)



Period	Stage	Males				Females			
		N at risk	Net Survival Probability			N at risk	Net Survival Probability		
			1-y (95%CI)	3-y (95%CI)	5-y (95%CI)		1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	<b>II</b>	63	61.0% (49.5%; 75.1%)	21.1% (12.6%; 35.4%)	12.1% (4.7%; 31.1%)	15	N<50	N<50	N<50
	<b>III</b>	315	48.9% (43.5%; 55.0%)	15.0% (10.4%; 21.5%)	4.9% (2.1%; 11.1%)	65	55.3% (44.3%; 69.1%)	25.1% (15.4%; 40.7%)	20.0% (11.0%; 36.5%)
	<b>IV</b>	150	36.0% (28.9%; 44.9%)	8.5% (4.5%; 16.1%)	FU<5y	35	N<50	N<50	N<50
	<b>X/NA</b>	229	44.3% (38.0%; 51.6%)	18.9% (13.9%; 25.7%)	9.9% (5.8%; 17.0%)	71	51.6% (41.1%; 64.9%)	36.4% (26.1%; 50.7%)	19.1% (9.6%; 37.8%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

## 6. CANCER MORTALITY



### 6.1. Mesothelioma mortality: by region

6.1.1. Mesothelioma mortality\* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR]																				ESR2013 (95%CI)		
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages	
Males																							
<b>Belgium</b>	0	0	0	0	0	0	0	0	0	2	0	8	9	38	29	32	36	27	9	3	193	3.9	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[2.0]	[2.5]	[12.4]	[10.9]	[18.4]	[27.6]	[34.8]	[32.1]	[55.0]	[3.4]	(3.3; 4.4)
Brussels	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1	0	1	0	0	0	5	1.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[3.7]	[9.6]	[6.0]	[0.0]	[11.8]	[0.0]	[0.0]	[0.0]	[0.8]	(0.2; 2.5)
Flanders	0	0	0	0	0	0	0	0	0	2	0	6	7	26	23	24	25	21	6	3	143	4.5	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[2.5]	[3.2]	[13.8]	[14.2]	[21.0]	[29.0]	[40.6]	[32.7]	[83.8]	[4.3]	(3.7; 5.2)	
Wallonia	0	0	0	0	0	0	0	0	0	0	0	2	1	10	5	8	10	6	3	0	45	3.1	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.6]	[0.9]	[10.2]	[5.8]	[16.5]	[27.8]	[28.7]	[39.6]	[0.0]	[2.5]	(2.2; 4.0)	
Females																							
<b>Belgium</b>	0	0	0	0	0	0	0	0	0	0	1	2	2	6	6	4	12	5	0	0	38	0.6	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.5]	[0.5]	[1.8]	[2.0]	[1.9]	[6.5]	[3.7]	[0.0]	[0.0]	[0.7]	(0.4; 0.8)	
Brussels	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	0	3	0.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[3.4]	[4.1]	[0.0]	[0.0]	[0.0]	[9.8]	[0.0]	[0.0]	[0.5]	(0.0; 1.2)

Region	N [CR]																				ESR2013 (95%CI)		
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages	
Flanders	0	0	0	0	0	0	0	0	0	0	1	2	1	3	5	4	9	3	0	0	28	0.7	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.4]	[0.8]	[0.5]	[1.6]	[2.9]	[3.0]	[7.8]	[3.5]	[0.0]	[0.0]	[0.8]	(0.4; 1.0)	
Wallonia	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	3	1	0	0	7	0.3	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.8]	[1.0]	[0.0]	[5.4]	[2.5]	[0.0]	[0.0]	[0.4]	(0.1; 0.6)

## 7. CANCER MORTALITY TRENDS



### 7.1. Mesothelioma mortality trends: by region

7.1.1. Mesothelioma mortality\* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period		
Belgium	<b>N</b>	155	151	167	188	172	184	181	174	189	203	196	190	207	208	185	198	188	193				
	<b>CR</b>	3.0	3.0	3.2	3.6	3.3	3.5	3.4	3.2	3.5	3.7	3.6	3.5	3.7	3.7	3.3	3.5	3.3	3.4				
	<b>ESR2013</b>	3.8	3.8	4.3	4.5	4.1	4.5	4.2	4.1	4.4	4.7	4.5	4.1	4.7	4.4	3.8	4.0	3.8	3.9	-0.4 (-1.0; 0.2)	2004-2021		
																				1.0 (0.1; 1.9)	2004-2015		
																					-2.9 (-4.7; -1.2)	2016-2021	
Brussels	<b>N</b>	4	4	4	7	5	9	5	3	5	7	7	2	10	9	3	8	4	5				
	<b>CR</b>	0.8	0.8	0.8	1.4	1.0	1.7	0.9	0.6	0.9	1.2	1.2	0.3	1.7	1.5	0.5	1.4	0.7	0.8				
	<b>ESR2013</b>	1.3	1.5	1.5	2.2	1.4	2.6	1.5	0.9	1.7	2.1	2.1	0.6	3.2	2.7	0.8	2.1	1.2	1.3				
																					-0.3 (-4.5; 4.0)	2004-2021	
Flanders	<b>N</b>	117	106	126	132	126	126	125	128	141	144	138	144	131	145	120	141	127	143				
	<b>CR</b>	3.9	3.6	4.2	4.4	4.1	4.1	4.1	4.1	4.5	4.6	4.4	4.5	4.1	4.5	3.7	4.3	3.9	4.3				
	<b>ESR2013</b>	4.8	4.3	5.1	5.1	4.9	4.8	4.7	4.9	5.2	5.4	5.1	5.0	4.7	4.8	3.9	4.6	4.0	4.5				
																						-0.8 (-1.4; -0.2)	2004-2021
																						0.8 (-0.3; 2.0)	2004-2014
																						-3.0 (-4.7; -1.3)	2015-2021
Wallonia	<b>N</b>	34	41	37	49	41	49	51	43	43	52	51	44	66	54	62	49	57	45				
	<b>CR</b>	2.1	2.5	2.2	2.9	2.4	2.9	3.0	2.5	2.5	3.0	2.9	2.5	3.8	3.1	3.5	2.8	3.2	2.5				

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
<b>ESR2013</b>	2.8	3.5	3.5	3.9	3.2	4.2	4.1	3.1	3.3	4.0	3.8	3.2	4.9	3.9	4.4	3.4	3.9	3.1	0.7 (-0.7; 2.1)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Mesothelioma mortality\* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	<b>N</b>	23	29	33	40	46	35	49	41	33	46	38	41	46	61	41	48	45	38		
	<b>CR</b>	0.4	0.5	0.6	0.7	0.8	0.6	0.9	0.7	0.6	0.8	0.7	0.7	0.8	1.1	0.7	0.8	0.8	0.7		
	<b>ESR2013</b>	0.4	0.6	0.6	0.7	0.8	0.6	0.9	0.7	0.6	0.8	0.7	0.7	0.7	1.0	0.6	0.7	0.7	0.6	2.4 (0.7; 4.2)	2004-2021
																				14.4 (5.2; 24.4)	2004-2008
																				-3.6 (-9.9; 3.1)	2009-2012
																				0.2 (-2.8; 3.3)	2013-2021
Brussels	<b>N</b>	1	1	1	3	2	2	4	3	2	3	2	5	1	5	4	5	5	3		
	<b>CR</b>	0.2	0.2	0.2	0.6	0.4	0.4	0.7	0.5	0.3	0.5	0.3	0.8	0.2	0.8	0.7	0.8	0.8	0.5		
	<b>ESR2013</b>	0.2	0.2	0.3	0.5	0.3	0.4	0.8	0.4	0.4	0.7	0.5	0.9	0.2	0.9	0.8	1.0	1.0	0.6	7.9 (3.8; 12.2)	2004-2021
Flanders	<b>N</b>	20	20	20	30	29	26	30	32	20	30	24	27	34	43	23	34	29	28		
	<b>CR</b>	0.7	0.7	0.6	1.0	0.9	0.8	0.9	1.0	0.6	0.9	0.7	0.8	1.0	1.3	0.7	1.0	0.9	0.8		
	<b>ESR2013</b>	0.7	0.7	0.7	0.9	0.9	0.8	0.9	0.9	0.6	0.8	0.7	0.7	0.9	1.1	0.6	0.8	0.8	0.7	0.3 (-1.3; 1.9)	2004-2021
Wallonia	<b>N</b>	2	8	12	7	15	7	15	6	11	13	12	9	11	13	14	9	11	7		
	<b>CR</b>	0.1	0.5	0.7	0.4	0.8	0.4	0.8	0.3	0.6	0.7	0.7	0.5	0.6	0.7	0.8	0.5	0.6	0.4		
	<b>ESR2013</b>	0.1	0.4	0.7	0.4	0.9	0.3	0.8	0.3	0.7	0.7	0.6	0.4	0.6	0.7	0.7	0.5	0.6	0.3	2.7 (-1.8; 7.4)	2004-2021
																				11.7 (0.4; 24.3)	2004-2012
																				-4.7 (-13.2; 4.6)	2013-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

\*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2022, Belgian Cancer Registry (BCR), 2025